Down 24.42% intraday: Universal Health Intl 2211.HK HKSE Feb 2026 at HKD0.61

2211.HK stock fell 24.42% to HKD 0.65 in intraday trading on the HKSE on 09 Feb 2026, turning the share into one of today’s top losers. Volume hit 3,339,720.00 shares, above the 50-day and 200-day averages, and the stock traded between HKD 0.61 and HKD 0.75. The drop follows weak sentiment for small-cap healthcare distributors in Hong Kong and renewed selling after the stock’s YTD decline of 55.09%. We examine drivers, valuation, technical signals and short-term price targets to frame a trading and risk view.

Market snapshot: 2211.HK stock intraday losses

Universal Health International Group Holding Limited (2211.HK) on the HKSE is trading at HKD 0.65, down 24.42% from yesterday’s close of HKD 0.86. Intraday range so far is HKD 0.61 to HKD 0.75 and volume is 3,339,720.00, a relative volume of 1.02 versus an avg of 2,861,909.00. The company’s market cap is HKD 60,080,133.00 and shares outstanding are 80,106,844.00.

Why the selloff: trading and sector context

The healthcare distribution sector in Hong Kong has shown cautious flows this week, and small-cap names have underperformed the broader healthcare index. For 2211.HK stock the intraday drop is consistent with a rapid unwind after recent near-term losses: 1-month change is -50.33% and YTD change is -55.09%. Market participants cite lower near-term liquidity and profit-taking after earlier rallies, not a single publicized corporate event. Sector comparisons show larger healthcare peers holding steadier margins, which raises short-term relative risk for smaller distributors.

Fundamentals and valuation: what the numbers say

Universal Health’s trailing EPS is -0.37 and the TTM P/E is -2.03, reflecting negative earnings. Key ratios: price-to-book is 0.17, price-to-sales is 0.07, and current ratio is 1.31. Inventory turnover stands at 9.13, and days sales outstanding is 23.22. Low valuation multiples versus book suggest deep value on accounting metrics, but negative margins and ROE of -7.91% signal operating stress.

Meyka AI rating and technical read for 2211.HK stock

Meyka AI rates 2211.HK with a score out of 100: 64.30 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technical indicators show oversold momentum: RSI 17.59, MACD histogram -0.04, and ADX 29.84. Short-term support sits at HKD 0.61 and resistance near the opening print at HKD 0.75.

Catalysts, news flow and risks for 2211.HK stock

Near-term catalysts include periodic earnings updates and sector liquidity shifts. The last earnings announcement was reported on 25 Feb 2025 and trailing metrics show negative profitability. Watch regulatory and distributor margin pressure in northeastern China. For broader market context see related market pages and news flow on [Investing.com](

Outlook and analyst-style price targets

We set three scenario price targets in HKD for traders and longer-term investors: conservative near-term target HKD 0.50 (downside), base 12-month target HKD 3.87, and bull three-year target HKD 7.82. Those reference the Meyka AI forecast and company fundamentals; the base target implies material upside but depends on margin recovery and steady volume. Forecasts are model-based projections and not guarantees.

Final Thoughts

Key takeaways: 2211.HK stock is a top intraday loser, down 24.42% to HKD 0.65 with 3,339,720.00 shares traded, reflecting heavy selling and oversold technicals. Fundamentals show a low price-to-book of 0.17 but negative EPS of -0.37 and ROE -7.91%, which raises execution risk for any recovery. Meyka AI’s forecast model projects a 12-month target of HKD 3.87, implying an upside of 495.70% versus the current price of HKD 0.65, but forecasts are model-based projections and not guarantees. Traders should watch support at HKD 0.61 and intraday resistance at HKD 0.75, while investors should balance valuation with the company’s negative margins and sector headwinds. For live quotes and additional research, see our Meyka AI platform and official news links.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.